|

HER3-DXd Clinical Trials

4 actively recruiting trials across 4 locations

Also known as: MK-1022, Patritumab Deruxtecan, U3-1402, patritumab deruxtecan, patritumab deruxtecan, U3-1402, MK-1022

Pipeline

Phase 2: 2Phase 1/2: 2

Top Sponsors

  • Merck Sharp & Dohme LLC3
  • Daiichi Sankyo1

Indications

  • Cancer4
  • Lung Cancer3
  • Esophageal Cancer2
  • Gastroesophageal Junction1
  • Gastroesophageal Adenocarcinoma1

Gilbert, Arizona1 trial

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Banner MD Anderson Cancer Center ( Site 0001)

Phase 1/2

Tucson, Arizona1 trial

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927)

Phase 1/2

Duarte, California1 trial

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

City of Hope

Phase 2

Lexington, Kentucky1 trial

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

University of Kentucky ( Site 0019)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.